Insider buying last 90 days
$162Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 24 | McEvoy Ashley director, officer: President and CEO | Purchase | $162K |
From Form 4 filings, dated to when each was filed.
NASDAQ: PODD
Insulet (PODD) Stock Analysis & Forecast
Sep 28 close
$133.11−3.02 (−2.2%)
Gekko Brief
AI summaryInsulet's week centers on efforts to improve retention among Type 2 diabetes customers using the Omnipod system, with the company rolling out enhanced sampling, adjusted incentives, improved support teams, and a broader rollout of the Omnipod Discover digital platform, alongside continued Omnipod 6 and global growth momentum. This follows Q2 2026 results in which revenue grew 22.7% to $801.7 million, exceeding guidance, though management flagged lower utilization and retention among Type 2 customers as a concern and the stock reacted with a -16.5% move on the last earnings date. Separate coverage notes the shares trading well below their 52-week high and underperforming peer DexCom (DXCM) and a medical devices ETF, while a securities investigation into the company was also announced.
The stock closes at $133.11, down 2.2%, sitting below both its 50-day average of $147.69 and 200-day average of $196.63, with the 50-day below the 200-day. The GekkoIndex reads 65.4, placing it in the Accumulation zone. Price sits 15.6% below Gekko Fair Value of $157.75.
Earnings are next due 5 November 2026, 37 days out, after close, falling outside a typical 20-day holding window. Smart money activity in the last 90 days shows one insider purchase and one Congressional buy with no sales. Seasonality over the next 20 trading days has averaged -1.4% across 5 years, rising in 2 of them, worth noting alongside the current trend readings.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Insulet price vs fair value
Close $133.11200-day averageGekko Fair Value $157.75
Insulet quick facts
- Market cap
- $9.22B
- P/E ratio
- 25.4
- Forward P/E
- 55
- EPS, TTM
- $5.34
- Revenue, TTM
- $3.05B
- Profit margin
- 12.3%
- Dividend yield
- —
- Beta
- 1.08
- Volume
- 1.72M avg 1.77M
- 1-year return
- −58.9%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±6.7%
- 50-day average
- $147.69
- 200-day average
- $196.63
- Next earnings
- Nov 5 after close
- Shares outstanding
- 69.35M
Insulet swing-trade checklist
Insulet scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $133.11 is below the 50-day ($147.69) and 200-day ($196.63) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
65.4, Accumulation
Reading 65.4 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
15.6% below
Price is 15.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 1 open-market insider purchase; Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.4% on average
From this point in the calendar, the next 20 trading days averaged −1.4% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Insulet stock chart and price history
Insulet closed at $133.11 on Sep 28, 2026, −58.9% over the past year, inside a 52-week range of $126.40 to $354.88.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −7.2%
- 3 months
- −15.6%
- 6 months
- −36.1%
- 1 year
- −58.9%
The full PODD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PODD in Gekko
Follow Insulet through every session
Put PODD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PODD in GekkoFree for 7 days. No credit card required.
About Insulet
Insulet designs and produces wearable insulin delivery devices for people who require insulin therapy, serving patients across the United States and other countries. Its Omnipod line is the centerpiece of the business, spanning the Omnipod 5 automated system that pairs a pod-embedded algorithm with a third-party continuous glucose monitor over Bluetooth, the Omnipod DASH system operated through a touchscreen personal diabetes manager, and the original Omnipod Insulin Management System.
Beyond diabetes care, the company manufactures pods used by Amgen in the Neulasta Onpro kit, a delivery mechanism intended to lower infection risk following intensive chemotherapy. Insulet reaches patients through pharmacy channels as well as a network of independent distributors, combining direct retail access with third-party distribution.
The company was incorporated in 2000 and is based in Acton, Massachusetts. Its shares trade on the NASDAQ under the ticker PODD.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- insulet.com
Insulet GekkoIndex: the smart money zone
Insulet’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.4, in the Accumulation zone, up 4.3 points over five sessions.
65.4Accumulation
Up 4.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | −1.0% | −7.9% | ||
| Accumulation (current zone) | 277 | −0.1% | −0.6% | ||
| Neutral | 324 | −0.1% | +0.7% | ||
| Distribution | 28 | +0.3% | −2.7% | ||
| Selling | 7 | Too few readings yet | |||
Average PODD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PODD price, zone by zone.Track PODD in Gekko
Is Insulet stock overvalued? Gekko Fair Value
Insulet trades 15.6% below Gekko Fair Value of $157.75, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Insulet shares are worth, recalculated every trading day.
$157.75
Gekko Fair Value, Sep 26, 2026
15.6% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open PODD in Gekko
Insulet insider and Congress trading
Insiders filed 1 open-market purchase in Insulet worth $162K, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 11 traded Aug 18 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Insulet has been buying back its own shares.
- Latest authorization
- $475.0M, Feb 18, 2026
- Bought back, quarter ended Jun 30, 2026
- $300.0M
- As a share of market cap
- 3.25%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PODD.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Insulet earnings: next date and track record
Insulet reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- $1.59
- Revenue estimate
- $833.3M
8 of 8reports beat the EPS estimate
±8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Insulet (PODD) reported Q2 2026 total revenue growth of 23% year-over-year on a constant currency basis, exceeding expectations. Adjusted operating margin expanded 140 basis points, while adjusted EPS grew approximately 42%. Global customer base grew 23% with record-near new customer starts. However, management flagged lower utilization and retention rates among type 2 diabetes customers as a notable challenge requiring commercial model adjustments.
- Guidance
- Management is revising assumptions and outlook to incorporate lower type 2 utilization and retention trends. Third quarter and full year 2026 guidance updates are expected, with commercial model enhancements being implemented to improve type 2 customer onboarding and retention.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $1.66 est $1.47 | $801.7M est $787.4M | −16.5% |
| May 6, 2026 | $1.42 est $1.19 | $761.7M est $729.9M | −4.3% |
| Feb 18, 2026 | $1.55 est $1.47 | $783.8M est $769.0M | +1.1% |
| Nov 6, 2025 | $1.24 est $1.14 | $706.3M est $678.4M | +1.7% |
| Aug 7, 2025 | $1.17 est $0.92 | $649.1M est $614.2M | +10.7% |
| May 8, 2025 | $1.02 est $0.79 | $569.0M est $543.3M | +17.5% |
| Feb 20, 2025 | $1.15 est $1.00 | $597.5M est $582.5M | −0.3% |
| Nov 7, 2024 | $0.90 est $0.76 | $372.6M est $519.5M | +12.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Insulet stock forecast and analyst price targets
Analysts’ average 12-month price target for Insulet is $171.91, +29.1% from the last close, from 18 firms rating the stock in the last 90 days.
$171.91consensus 12-month target, +29.1% from the last close
Now $133.11Avg $171.91
Low $144High $185
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 13 | Citi | $150 | +12.7% |
| Aug 12 | UBS | $150 | +12.7% |
| Aug 6 | J.P. Morgan | $152 | +14.2% |
| Aug 6 | BTIG | — | — |
| Aug 6 | Leerink Partners | $145 | +8.9% |
−0.6%average 20-day move after past Accumulation readings
−1.4%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Insulet seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Insulet averaged −1.4% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.7% | 1 of 5 |
| Next 10 trading days | −1.9% | 2 of 5 |
| Next 15 trading days | −3.1% | 2 of 5 |
| Next 20 trading days | −1.4% | 2 of 5 |
| Next 30 trading days | +8.6% | 5 of 5 |
For scale, PODD’s typical 20-trading-day move in either direction is about 6.7%.
Insulet market cap and key statistics
Insulet’s market cap is $9.22B, with a P/E ratio of 25.4 and revenue of $3.05B over the last twelve months.
Valuation
- Market cap
- $9.22B
- P/E ratio
- 25.4
- Forward P/E
- 55
- EPS, TTM
- $5.34
- Gekko Fair Value
- $157.75
Trading
- Volume
- 1.72M
- Avg volume, 20 days
- 1.77M
- 52-week high
- $354.88
- 52-week low
- $126.40
- Shares outstanding
- 69.35M
Financials
- Revenue, TTM
- $3.05B
- Profit margin
- 12.3%
- Return on equity
- 26%
- Quarterly earnings growth, YoY
- +328.6%
Risk and income
- Beta
- 1.08
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±6.7%
Insulet stock news this week
Coverage of Insulet this week reads positive: 4 positive, 4 neutral and 3 negative headlines.
- Why Insulet (PODD) is a Top Growth Stock for the Long-TermZacks Investment Research, Sep 25
- Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain MomentumYahoo Finance, Sep 25
- Insulet stock heads into the open after a 0.1 percent riseAD HOC NEWS, Sep 25
- Insulet Corporation (PODD) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha, Sep 24
- Bronstein, Gewirtz & Grossman, LLC Encourages Insulet Corporation (PODD) Stockholders to Inquire about Securities InvestigationACCESS Newswire, Sep 24
- How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?inkl, Sep 24
Insulet peers
Insulet’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Insulet stock FAQ
What is Insulet’s market cap?
Insulet’s market cap is $9.22B at the Sep 28, 2026 close of $133.11, with 69.35M shares outstanding. The shares trade on a P/E ratio of 25.4.
What is the Insulet stock forecast?
The consensus analyst 12-month price target for Insulet is $171.91, +29.1% from the last close. Of the 18 firms that rated the stock in the last 90 days, 9 rate it a buy, 9 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Insulet stock overvalued or undervalued?
On Gekko’s estimate Insulet is undervalued: the Sep 28, 2026 close of $133.11 is 15.6% below Gekko Fair Value of $157.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Insulet report earnings next?
Insulet is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of $1.59 per share on revenue of $833.3M. Insulet beat the earnings estimate in 8 of its last 8 reports, moving 8% on average across the report.
What is Insulet’s 52-week high and low?
Insulet’s 52-week high is $354.88 and its 52-week low is $126.40; it closed at $133.11 on Sep 28, 2026, −58.9% over the past year.
Is Insulet stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Insulet the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.